Atossa Therapeutics, Inc. (ATOS)
Pre-Market:
| Previous Close | 1.0000 |
| Open | 1.0400 |
| Bid | 1.0100 x 2900 |
| Ask | 1.0500 x 1800 |
| Day's Range | 1.0200 - 1.0702 |
| 52 Week Range | 0.8400 - 4.3100 |
| Volume | |
| Avg. Volume | 1,376,882 |
| Market Cap | 132.955M |
| Beta (5Y Monthly) | 1.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended June 30, 2022, and provides an update on recent company developments. Key developments from Q2 2022 and to date include: Completed dosing in both Part B and Part C (of fo
- GlobeNewswire
Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers
Atossa Plans to Initiate a New Development Path in Patients with Compromised Lung-Function Resulting from Cancer TreatmentSEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces it has completed dosing participants in Part C of its Phase 1/2a
- GlobeNewswire
Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations
SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces the appointment of Charles Butler, a 25-year veteran in the healthcare communications space, as vice president of investor relations and public relations. “As Atossa continue
